The global antisense oligonucleotides market is projected to amass revenue of around USD 5,519.6 million by 2033, up from USD 2,913.5 million in 2023 moving forward with a CAGR of 6.6% during the forecast period.
The antisense oligonucleotides adoption trends are significantly swayed by their promising treatment options for a range of medical disorders. Moreover, they also facilitate the development of therapeutics affecting protein targets that cannot be treated with protein therapeutics, propelling the market growth. They target a particular malfunctioning gene, interfere with RNA function at the cellular level, and also be silenced or modulated and the same is catching the attention of market players.
The rising demand for antisense oligonucleotides is attributed to its aid in modifying the immune system that facilitates the treatment of a wide range of autoimmune disorders - that cannot be treated with available drugs.
It is easy to scale up the commercial scale GMP production of these oligonucleotides compared to other biologic therapies, spurring the adoption of antisense oligonucleotides.
Moreover, the market is enhanced by the minimal side effects of antisense oligonucleotides, which are controlled with ease as compared to other classes of drugs.
The antisense oligonucleotides sector has witnessed four FDA approvals [fomivirsen (Vitravene) approved in 1998 - which was discontinued due to low demand; pegaptanib (Macugen) in 2004; mipomersen (Kynamro) in 2013; and eteplirsen (Exondys 51) in 2016).
However, this market is yet to achieve recognition as a valuable drug category like biologics, small molecules, and gene and cell therapy.
However, this was projected to change with the approval of nusinersen (Spinraza) for treating spinal muscular atrophy (SMA), which is one of the most common genetic causes of infant mortality with no approved treatments.
Even when the market performance of antisense oligonucleotides is not predictable as like other segments of the industry, the market outlook is positively influenced by the leading players in the market and the amount of research and development investments.
Attributes | Details |
---|---|
Antisense Oligonucleotides Market CAGR (2023 to 2033) | 6.6% |
Antisense Oligonucleotides Market Size (2023) | USD 2,913.5 million |
Antisense Oligonucleotides Market Size (2033) | USD 5,519.6 million |
A strong pipeline of antisense oligonucleotides and increased focus on a large number of product approvals and commercialization are likely to expand the global antisense oligonucleotides sector size.
Moreover, significant advances in the field of antisense oligonucleotides at a therapeutic or clinical level are further contributing to the growth of the global market.
However, the global antisense oligonucleotides business is grappling with numerous challenges related to the diversity of oligonucleotides, delivery, and regulatory complexity.
Despite several advancements at clinical levels, the delivery of active oligonucleotides to the actual site within target cells is still one of the key challenges hindering the growth of the global antisense oligonucleotides sector. In addition to this, developing a new set of unique regulatory guidelines is also expected to hamper the market statistics.
Countries | Market Share (2022) |
---|---|
United States | 58% |
Germany | 3.3% |
Japan | 2.9% |
North America clearly dominates the global antisense oligonucleotides industry due to a strong product pipeline and an increasing number of FDA approvals in the region, contributing to the region’s market share of 60.9% in 2022.
For instance, the international biotechnology company Biogen Inc.'s Nusinersen, sold as Spinraza, received FDA approval in the USA in 2018. Health infrastructures and an increase in the use of oligonucleotides in the development of innovative pharmacological therapies are additional factors driving market expansion.
In 2022, the Europe antisense oligonucleotides sector captured a share of 14.3%. In order to improve their product portfolio for antisense oligonucleotides, key players in Europe are concentrating on strategic mergers and acquisitions, in turn spurring the market growth in Europe.
For instance, in 2014, the multinational pharmaceutical and biopharmaceutical company AstraZeneca Plc. merged with the pharmaceutical firm Ionis Pharmaceuticals. Additionally, it is anticipated that a strong pipeline of important companies aids the market growth to some level.
While many organizations are working on RNA-based treatments and vaccines, including well-known companies like Pfizer, BioNtech, Moderna, etc., a few biotech start-ups are also emerging, shaping the market trends.
Examples:
The company's tiny molecule medications bind to targets that were previously believed to be unreachable as well as those that were confirmed using genetic and pharmacological techniques.
These medications use multiple ways to either decrease RNA translation or splicing. Drugs for oncology, dyslipidemia, and uncommon disorders are in the startup's development.
The company's top therapeutic candidate for type 1 myotonic dystrophy is an anti-microRNA (DM1). The start-up's anti-miRs are shown to suppress microRNAs that repress MBNL1/2 genes in DM1 in muscle biopsies of patients.
The market for antisense oligonucleotides is fairly consolidated, with a few competitors gaining a significant growing share. The market participants for antisense oligonucleotides are heavily invested in research and development. These activities assist the participants in developing novel formulations that are advantageous to the user.
A couple of recent developments are:
The agreement improves MilliporeSigma's capacity to produce and develop mRNA for its clients' usage in Covid-19 and numerous other diseases-related vaccines, therapies, and diagnostics.
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by Application , 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by Application , 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by Application , 2018 to 2033
Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Western Europe Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 15: Western Europe Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 16: Western Europe Market Value (US$ Million) Forecast by Application , 2018 to 2033
Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: Eastern Europe Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 19: Eastern Europe Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 20: Eastern Europe Market Value (US$ Million) Forecast by Application , 2018 to 2033
Table 21: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: South Asia and Pacific Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 23: South Asia and Pacific Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 24: South Asia and Pacific Market Value (US$ Million) Forecast by Application , 2018 to 2033
Table 25: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: East Asia Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 27: East Asia Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 28: East Asia Market Value (US$ Million) Forecast by Application , 2018 to 2033
Table 29: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 30: Middle East and Africa Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 31: Middle East and Africa Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 32: Middle East and Africa Market Value (US$ Million) Forecast by Application , 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Drug, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Indication, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Application , 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by Application , 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by Application , 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by Application , 2023 to 2033
Figure 17: Global Market Attractiveness by Drug, 2023 to 2033
Figure 18: Global Market Attractiveness by Indication, 2023 to 2033
Figure 19: Global Market Attractiveness by Application , 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Drug, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Indication, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by Application , 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by Application , 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Application , 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Application , 2023 to 2033
Figure 37: North America Market Attractiveness by Drug, 2023 to 2033
Figure 38: North America Market Attractiveness by Indication, 2023 to 2033
Figure 39: North America Market Attractiveness by Application , 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Drug, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Indication, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by Application , 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by Application , 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Application , 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Application , 2023 to 2033
Figure 57: Latin America Market Attractiveness by Drug, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Indication, 2023 to 2033
Figure 59: Latin America Market Attractiveness by Application , 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Western Europe Market Value (US$ Million) by Drug, 2023 to 2033
Figure 62: Western Europe Market Value (US$ Million) by Indication, 2023 to 2033
Figure 63: Western Europe Market Value (US$ Million) by Application , 2023 to 2033
Figure 64: Western Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Western Europe Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 71: Western Europe Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 74: Western Europe Market Value (US$ Million) Analysis by Application , 2018 to 2033
Figure 75: Western Europe Market Value Share (%) and BPS Analysis by Application , 2023 to 2033
Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by Application , 2023 to 2033
Figure 77: Western Europe Market Attractiveness by Drug, 2023 to 2033
Figure 78: Western Europe Market Attractiveness by Indication, 2023 to 2033
Figure 79: Western Europe Market Attractiveness by Application , 2023 to 2033
Figure 80: Western Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: Eastern Europe Market Value (US$ Million) by Drug, 2023 to 2033
Figure 82: Eastern Europe Market Value (US$ Million) by Indication, 2023 to 2033
Figure 83: Eastern Europe Market Value (US$ Million) by Application , 2023 to 2033
Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 94: Eastern Europe Market Value (US$ Million) Analysis by Application , 2018 to 2033
Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by Application , 2023 to 2033
Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by Application , 2023 to 2033
Figure 97: Eastern Europe Market Attractiveness by Drug, 2023 to 2033
Figure 98: Eastern Europe Market Attractiveness by Indication, 2023 to 2033
Figure 99: Eastern Europe Market Attractiveness by Application , 2023 to 2033
Figure 100: Eastern Europe Market Attractiveness by Country, 2023 to 2033
Figure 101: South Asia and Pacific Market Value (US$ Million) by Drug, 2023 to 2033
Figure 102: South Asia and Pacific Market Value (US$ Million) by Indication, 2023 to 2033
Figure 103: South Asia and Pacific Market Value (US$ Million) by Application , 2023 to 2033
Figure 104: South Asia and Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: South Asia and Pacific Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 109: South Asia and Pacific Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 110: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 111: South Asia and Pacific Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 112: South Asia and Pacific Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 113: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 114: South Asia and Pacific Market Value (US$ Million) Analysis by Application , 2018 to 2033
Figure 115: South Asia and Pacific Market Value Share (%) and BPS Analysis by Application , 2023 to 2033
Figure 116: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Application , 2023 to 2033
Figure 117: South Asia and Pacific Market Attractiveness by Drug, 2023 to 2033
Figure 118: South Asia and Pacific Market Attractiveness by Indication, 2023 to 2033
Figure 119: South Asia and Pacific Market Attractiveness by Application , 2023 to 2033
Figure 120: South Asia and Pacific Market Attractiveness by Country, 2023 to 2033
Figure 121: East Asia Market Value (US$ Million) by Drug, 2023 to 2033
Figure 122: East Asia Market Value (US$ Million) by Indication, 2023 to 2033
Figure 123: East Asia Market Value (US$ Million) by Application , 2023 to 2033
Figure 124: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 125: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: East Asia Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 129: East Asia Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 130: East Asia Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 131: East Asia Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 132: East Asia Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 134: East Asia Market Value (US$ Million) Analysis by Application , 2018 to 2033
Figure 135: East Asia Market Value Share (%) and BPS Analysis by Application , 2023 to 2033
Figure 136: East Asia Market Y-o-Y Growth (%) Projections by Application , 2023 to 2033
Figure 137: East Asia Market Attractiveness by Drug, 2023 to 2033
Figure 138: East Asia Market Attractiveness by Indication, 2023 to 2033
Figure 139: East Asia Market Attractiveness by Application , 2023 to 2033
Figure 140: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 141: Middle East and Africa Market Value (US$ Million) by Drug, 2023 to 2033
Figure 142: Middle East and Africa Market Value (US$ Million) by Indication, 2023 to 2033
Figure 143: Middle East and Africa Market Value (US$ Million) by Application , 2023 to 2033
Figure 144: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033
Figure 145: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 146: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 147: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 148: Middle East and Africa Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 149: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 150: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 151: Middle East and Africa Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 152: Middle East and Africa Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 153: Middle East and Africa Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 154: Middle East and Africa Market Value (US$ Million) Analysis by Application , 2018 to 2033
Figure 155: Middle East and Africa Market Value Share (%) and BPS Analysis by Application , 2023 to 2033
Figure 156: Middle East and Africa Market Y-o-Y Growth (%) Projections by Application , 2023 to 2033
Figure 157: Middle East and Africa Market Attractiveness by Drug, 2023 to 2033
Figure 158: Middle East and Africa Market Attractiveness by Indication, 2023 to 2033
Figure 159: Middle East and Africa Market Attractiveness by Application , 2023 to 2033
Figure 160: Middle East and Africa Market Attractiveness by Country, 2023 to 2033
Robust product pipeline and rising FDA approvals in the region dominate the market.
The rising number of FDA approvals is the key opportunity in the market.
Advanced pharmacological techniques are the key trend.
Promising treatment offers for medical disorders.
The market is forecast to register a CAGR of 6.6% through 2033.
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.